Profile data is unavailable for this security.
About the company
Paxman AB (publ) is a Sweden-based developer of scalp cooling technology. The cooling system aims to reduce the risk of hair loss connected with cytostatic treatment of cancer. The Company offers a stand-alone, mobile electric cooling unit, which markets under the name Paxman Scalp Cooler, which is a liquid-based cooling system that cools down the patients scalp through the silicone hat. The product has two versions - for one or two patients to be cooled at once. Each device contains a built-in touch screen with a menu-controlled graphic user interface to monitor the process. The lightweight system enables patient to participate in other activities. The Company’s primary markets are Great Britain, Scandinavian countries, the Netherlands, Belgium and Australia.
- Revenue in SEK (TTM)295.08m
- Net income in SEK4.92m
- Incorporated2016
- Employees142.00
- LocationPaxman AB (publ)Pirgatan 13KARLSHAMN 374 35SwedenSWE
- Phone+46 704543791
- Websitehttps://www.paxman.se/
More ▼
Mergers & acquisitions
| Acquired company | PAX:STO since announced | Transaction value |
|---|---|---|
| Dignitana AB | -23.62% | 15.19m |
Data delayed at least 15 minutes, as of Feb 10 2026 12:05 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioPorto A/S | 52.02m | -123.49m | 693.17m | 48.00 | -- | 12.72 | -- | 13.33 | -0.1973 | -0.1973 | 0.083 | 0.0774 | 0.4132 | 2.55 | 4.69 | 962,131.60 | -98.08 | -65.22 | -133.92 | -88.74 | 63.90 | 64.15 | -237.40 | -222.22 | 1.71 | -- | 0.1916 | -- | 17.07 | 6.36 | -21.15 | -- | -20.56 | -- |
| OssDsign AB | 180.16m | -50.99m | 704.69m | 32.00 | -- | 2.27 | -- | 3.91 | -0.5493 | -0.5493 | 2.06 | 2.80 | 0.5109 | 0.3672 | 6.95 | 5,629,938.00 | -14.46 | -25.42 | -16.05 | -28.59 | 96.29 | 85.57 | -28.30 | -82.42 | 6.33 | -13.77 | 0.0044 | -- | 34.51 | 48.59 | -2.68 | -- | 24.28 | -- |
| Senzime AB (publ) | 89.71m | -120.62m | 710.61m | 50.00 | -- | 2.04 | -- | 7.92 | -0.8672 | -0.8672 | 0.6394 | 2.22 | 0.234 | 1.73 | 5.99 | 1,794,120.00 | -31.47 | -35.09 | -34.04 | -37.52 | 41.86 | 8.75 | -134.46 | -400.65 | 4.30 | -7.70 | 0.0399 | -- | 63.55 | 54.18 | 11.50 | -- | 40.12 | -- |
| Omda AS | 442.41m | -28.20m | 804.30m | 260.00 | -- | 25.36 | 29.13 | 1.82 | -1.51 | -1.51 | 23.59 | 1.63 | 0.6793 | 26.59 | 21.70 | 1,772,075.00 | -4.33 | -5.14 | -5.39 | -6.63 | 93.69 | 91.09 | -6.37 | -10.32 | 0.6483 | 0.5281 | 0.9359 | -- | 3.45 | 15.80 | -163.95 | -- | -15.57 | -- |
| Gentian Diagnostics ASA | 160.71m | 39.85m | 821.79m | 63.00 | 20.92 | 4.37 | 17.03 | 5.11 | 2.73 | 2.73 | 11.07 | 13.10 | 0.8181 | 1.63 | 7.83 | 2,738,365.00 | 20.29 | -2.99 | 22.99 | -3.36 | 55.06 | 44.66 | 24.80 | -5.84 | 4.16 | -- | 0.0094 | -- | 12.52 | 25.96 | 525.37 | -- | 22.08 | -- |
| Optomed Oyj | 184.77m | -61.07m | 904.22m | 112.00 | -- | 3.85 | -- | 4.89 | -0.2915 | -0.2915 | 0.8803 | 1.03 | 0.5847 | 2.40 | 5.47 | 151,147.80 | -19.33 | -14.59 | -23.47 | -17.41 | 64.64 | 65.60 | -33.05 | -31.36 | 1.60 | -20.89 | 0.1221 | -- | -0.3974 | 0.084 | -22.72 | -- | 8.10 | -- |
| Nexstim Oyj | 106.99m | -3.01m | 966.15m | 40.00 | -- | 28.47 | 136.93 | 9.03 | -0.042 | -0.042 | 1.47 | 0.4426 | 0.8553 | 0.5613 | 4.66 | 251,616.80 | -2.40 | -12.40 | -4.17 | -20.76 | 94.36 | 95.09 | -2.81 | -16.29 | 1.08 | 0.7835 | 0.6002 | -- | 20.55 | 21.14 | 32.79 | -- | 15.13 | -- |
| Sedana Medical AB (publ) | 197.61m | -40.65m | 990.39m | 117.00 | -- | 1.09 | -- | 5.01 | -0.4092 | -0.4092 | 1.99 | 9.14 | 0.2012 | 1.46 | 9.47 | 2,670,406.00 | -4.14 | -4.90 | -4.34 | -5.16 | 70.47 | 68.32 | -20.57 | -30.26 | 3.28 | -21.90 | 0.0045 | -- | 16.17 | 20.06 | 82.09 | -- | 26.45 | -- |
| ADDvise Group AB (publ) | 1.62bn | 4.30m | 1.04bn | 615.00 | 19.97 | 0.943 | 9.38 | 0.6417 | 0.0864 | 0.0864 | 3.44 | 1.83 | 0.5167 | 7.91 | 4.96 | 2,534,790.00 | 0.1399 | 3.41 | 0.174 | 4.28 | 39.91 | 46.52 | 0.2708 | 6.06 | 0.7562 | 1.62 | 0.5251 | 0.4389 | 21.68 | 36.71 | -13.04 | 85.85 | 52.63 | -- |
| C Rad AB | 457.70m | 23.25m | 1.05bn | 107.00 | 46.08 | 3.03 | 30.90 | 2.29 | 0.6922 | 0.6922 | 13.58 | 10.53 | -- | -- | -- | 4,623,273.00 | -- | 8.44 | -- | 11.73 | 51.45 | 45.00 | 5.08 | 8.28 | 2.98 | 3.31 | 0.0252 | 0.00 | 10.45 | 17.96 | 58.88 | -- | -9.15 | -- |
| Paxman AB (publ) | 295.08m | 4.92m | 1.06bn | 142.00 | 164.69 | 2.47 | 42.88 | 3.58 | 0.2757 | 0.2757 | 14.26 | 18.38 | 0.8486 | 3.45 | 4.71 | 2,810,305.00 | 1.37 | 0.8426 | 1.60 | 1.20 | 67.34 | 68.75 | 1.61 | 0.7966 | 4.07 | 1.71 | 0.0245 | 0.00 | 20.41 | 24.30 | 382.55 | 70.92 | -3.73 | -- |
| BICO Group AB | 1.51bn | -1.26bn | 1.19bn | 586.00 | -- | 0.6688 | -- | 0.7874 | -17.83 | -9.68 | 21.34 | 25.67 | 0.3269 | 3.30 | 3.65 | 2,074,793.00 | -27.41 | -- | -35.79 | -- | 36.91 | -- | -83.83 | -- | 1.13 | -- | 0.4174 | -- | -3.19 | -- | 88.56 | -- | -- | -- |
| Surgical Science Sweden AB | 975.04m | 69.83m | 1.23bn | 328.00 | 17.67 | 0.2869 | 8.48 | 1.27 | 1.37 | 1.37 | 19.11 | 84.27 | 0.2051 | 1.72 | 7.09 | 3,558,537.00 | 1.47 | 3.91 | 1.55 | 4.18 | 66.61 | 68.94 | 7.16 | 21.55 | 3.44 | -- | 0.0004 | 0.00 | 0.1398 | 54.17 | -43.73 | 59.89 | 39.76 | -- |
| Stille AB | 552.55m | 40.41m | 1.31bn | 208.00 | 32.44 | 1.89 | 14.80 | 2.37 | 4.50 | 4.50 | 62.09 | 77.10 | 0.531 | 1.55 | 7.66 | 3,891,176.00 | 3.88 | 6.20 | 4.55 | 7.11 | 52.45 | 47.21 | 7.31 | 9.48 | 1.87 | -- | 0.00 | 16.29 | 93.27 | 29.47 | 118.44 | 20.53 | 13.88 | -- |
| Genovis AB | 116.63m | 21.19m | 1.35bn | 36.00 | 63.41 | 5.13 | 41.92 | 11.58 | 0.3225 | 0.3225 | 1.78 | 3.99 | 0.3404 | -- | -- | 3,644,719.00 | 6.18 | 15.62 | 6.57 | 17.56 | 90.28 | 88.86 | 18.16 | 25.11 | -- | -- | 0.2171 | 0.00 | -17.62 | 16.58 | -46.48 | 28.08 | -1.42 | -- |
| Nordhealth As | 534.04m | -113.17m | 1.47bn | 450.00 | -- | 3.71 | -- | 2.75 | -1.54 | -1.54 | 7.25 | 9.41 | 0.6188 | -- | 8.10 | 1,394,815.00 | -13.11 | -- | -14.99 | -- | 82.95 | -- | -21.19 | -- | -- | -- | 0.00 | -- | 24.03 | -- | 31.06 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Paxman AB (publ)'s reporting currency: Swedish Krona SEK
20.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| L�nsf�rs�kringar Fondf�rvaltning ABas of 28 Jan 2026 | 1.12m | 4.82% |
| Eiffel Investment Group SASas of 28 Jan 2026 | 1.07m | 4.60% |
| Andra AP-fondenas of 28 Jan 2026 | 999.44k | 4.29% |
| Alcur Fonder ABas of 30 Dec 2024 | 444.19k | 1.91% |
| Origo Fonder ABas of 31 Jan 2026 | 243.77k | 1.05% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 31 Dec 2025 | 226.28k | 0.97% |
| Aktia Bank Plc (Investment Management)as of 31 Oct 2025 | 202.00k | 0.87% |
| Carnegie Fonder ABas of 30 Dec 2025 | 200.00k | 0.86% |
| Schroder Investment Management (Europe) SA (Finland)as of 30 Jun 2025 | 196.00k | 0.84% |
| SEB Funds ABas of 31 Dec 2025 | 150.00k | 0.65% |
More ▼
Data from 30 Sep 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
